Literature DB >> 28692029

Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma.

M Damlaj1, S Ghazi1, G Syed2, T Pasha1, G Gmati1, H Salama1, O Ali1, K A Abuelgasim1, M Al-Zahrani1, A Hejazi1, A Al Askar1,3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28692029     DOI： 10.1038/bmt.2017.143

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.

Authors:  Raynier Devillier; Diane Coso; Luca Castagna; Isabelle Brenot Rossi; Antonella Anastasia; Arturo Chiti; Vadim Ivanov; Jean Marc Schiano; Armando Santoro; Christian Chabannon; Monica Balzarotti; Didier Blaise; Reda Bouabdallah
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

3.  Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.

Authors:  Jacob P Smeltzer; Amanda F Cashen; Qin Zhang; Andrew Homb; Farrokh Dehdashti; Camille N Abboud; John F Dipersio; Keith E Stockerl-Goldstein; Geoffrey L Uy; Ravi Vij; Peter Westervelt; Nancy L Bartlett; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-03       Impact factor: 5.742

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

Authors:  Craig H Moskowitz; Matt J Matasar; Andrew D Zelenetz; Stephen D Nimer; John Gerecitano; Paul Hamlin; Steven Horwitz; Alison J Moskowitz; Ariela Noy; Lia Palomba; Miguel-Angel Perales; Carol Portlock; David Straus; Jocelyn C Maragulia; Heiko Schoder; Joachim Yahalom
Journal:  Blood       Date:  2011-12-19       Impact factor: 22.113

6.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Authors:  Sally F Barrington; N George Mikhaeel; Lale Kostakoglu; Michel Meignan; Martin Hutchings; Stefan P Müeller; Lawrence H Schwartz; Emanuele Zucca; Richard I Fisher; Judith Trotman; Otto S Hoekstra; Rodney J Hicks; Michael J O'Doherty; Roland Hustinx; Alberto Biggi; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

Review 7.  Positron emission tomographic scans in lymphoma: convention and controversy.

Authors:  Stephen M Ansell; James O Armitage
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

8.  Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

Authors:  Elias Jabbour; Chitra Hosing; Gregory Ayers; Rodolfo Nunez; Paolo Anderlini; Barbara Pro; Issa Khouri; Anas Younes; Fredrick Hagemeister; Larry Kwak; Luis Fayad
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

Review 9.  High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.

Authors:  Michaela Rancea; Ina Monsef; Bastian von Tresckow; Andreas Engert; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2013-06-20

10.  Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Authors:  Peter Johnson; Massimo Federico; Amy Kirkwood; Alexander Fosså; Leanne Berkahn; Angelo Carella; Francesco d'Amore; Gunilla Enblad; Antonella Franceschetto; Michael Fulham; Stefano Luminari; Michael O'Doherty; Pip Patrick; Thomas Roberts; Gamal Sidra; Lindsey Stevens; Paul Smith; Judith Trotman; Zaid Viney; John Radford; Sally Barrington
Journal:  N Engl J Med       Date:  2016-06-23       Impact factor: 91.245
View more
  2 in total

Review 1.  Role of Radiomics-Based Baseline PET/CT Imaging in Lymphoma: Diagnosis, Prognosis, and Response Assessment.

Authors:  Han Jiang; Ang Li; Zhongyou Ji; Mei Tian; Hong Zhang
Journal:  Mol Imaging Biol       Date:  2022-01-14       Impact factor: 3.484

2.  Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma.

Authors:  Khadega A Abuelgasim; Mohsen Alzahrani; Yousef Alsharhan; Moataz Khairi; Mohammed Hommady; Giamal Gmati; Hind Salama; Osama Ali; Bader Alahmari; Emad M Masuadi; Ahmed Alaskar; Ayman Alhejazi; Moussab Damlaj
Journal:  Bone Marrow Transplant       Date:  2019-01-30       Impact factor: 5.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.